Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Endocrinology

Articles with lock require a GLG News subscription
Posted September 21, 2007
New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years
Analysis of: New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years | www.pipelinereview.com
Author: GLG Member Program Contributor
Long term studies of Exubera do little to reassure the product's safety. This is especially true in the face of new insulin pens that are safe, effective and makes it very easy to administer insulin.
Posted September 21, 2007
Metabasis Therapeutics Presents Promising Preclinical Results with Its Novel Glucagon Antagonist for the Treatment of Type 2 Diabetes
Analysis of: Metabasis Therapeutics Presents Promising Preclinical Results with Its Novel Glucagon Antagonist for the Treatment of Type 2 Diabetes | www.pipelinereview.com
Author: GLG Member Program Contributor
Glucagon receptor antagonists sound like they will be a welcome addition to the current medications used to treat diabetes.  Although, they will probably only be helpful in type 2 diabetes because that is where the pancreas is still functioning, they are targetting a pathway that has not yet been...
Posted September 21, 2007
Type 2 Diabetes Patients Taking ACTOS (Pioglitazone HCl) 22% Less Likely To Be Hospitalized For Heart Attack Than Those Taking Rosiglitazone
Analysis of: Type 2 Diabetes Patients Taking ACTOS (Pioglitazone HCl) 22% Less Likely To Be Hospitalized For Heart Attack Than Those Taking Rosiglitazone | www.medicalnewstoday.com
Author: GLG Member Program Contributor
This study confirms previous work, which is still questionable. Using Avandia exposes the physician to a legal minefield.
Posted September 21, 2007
Phase 3 study confirms that liraglutide treatment leads to both glucose and weight reduction with a low risk of hypoglycaemic events
Analysis of: Phase 3 study confirms that liraglutide treatment leads to both glucose and weight reduction with a low risk of hypoglycaemic events | www.pipelinereview.com
Author: GLG Member Program Contributor
A once  a day GLP-1 analog will simplify its use. There is a low incidence of hypoglycemia which favors it over some insulins. Its method of action is clearly physiologic. If nausea is not a major issue, it will have a major role in therpy, in light of the problems that are arising from other ...
Posted September 21, 2007
New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years
Analysis of: New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years | www.pipelinereview.com
Author: GLG Member Program Contributor
There is no question that Exubera works. the problem is with the delivery system If willing to use will work, but how many are willing to use it? Also how many ae willing to undergo the extra testing that is needed?
Posted September 20, 2007
New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years
Analysis of: New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years | www.pipelinereview.com
Author: GLG Member Program Contributor
European results in a limited number of patients on Exubera for 2-8 years Effectiveness and safety in about a 1/3 of study participants after 8 years
Posted September 19, 2007
Sanofi aims to show there's still life in Acomplia
Analysis of: Sanofi aims to show there's still life in Acomplia | www.reuters.com
Author: GLG Member Program Contributor
Sanofi after facing defeat with the FDA hopes to prove with further clinical trials the satety and effectivenss of Accomplia...If successful, this might be huge.
Posted September 18, 2007
Sanofi aims to show there's still life in Acomplia
Analysis of: Sanofi aims to show there's still life in Acomplia | www.reuters.com
Author: GLG Member Program Contributor
- Accomplia has been PROVEN to cause depression and suicidal ideation - no matter what studies Sanofi Aventis does, it will not be approved   by the F.D.A.
Posted September 18, 2007
XOMA Initiates Phase 1 European Trial in Diabetes for XOMA 052, a Novel Anti-IL-1 Antibody Designed to Target Diabetes, Rheumatoid Arthritis and Other Inflammatory Diseases
Analysis of: XOMA Initiates Phase 1 European Trial in Diabetes for XOMA 052, a Novel Anti-IL-1 Antibody Designed to Target Diabetes, Rheumatoid Arthritis and Other Inflammatory Diseases | www.pipelinereview.com
Author: GLG Member Program Contributor
I would have thought that Kineret (AMGN) would have dissuaded others from the IL-1 pathway.  I guess not.
Posted September 17, 2007
Actos Bests Avandia in New Study
Analysis of: Actos Bests Avandia in New Study | www.businessweek.com
Author: GLG Member Program Contributor
This study confirms to some degree the cardiac problems associated with the use of Avandia.  It is hard to see how anyone will feel comfortable using it, in light of our legal system.
Previous Page : 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next171 to 180 of 363

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-08-30T05:45:15.877